Mapping antimalarial drug resistance markers in Plasmodium falciparum isolates across Benin
Background Perennial malaria chemoprevention (PMC) with sulfadoxine-pyrimethamine (SP) is recommended for children less than two years of age. However, SP resistance, which is attributable to a combination of mutations in the Pfdhps and the Pfdhfr genes, reduces the duration of SP protective efficacy. The present study aims to provide geographically complete information on the status of antimalarial drug resistance in P. falciparum across Benin to inform the subnational tailoring of antimalarial chemoprevention and treatment. Method We conducted cross-sectional sampling of parasites from each of the 12 administrative departments of Benin during 2023. In each department, health facilities where the Ministry of Health conduct routine TES were chosen as sites of collection. Finger-prick blood samples from consenting symptomatic malaria patients of all ages were collected and the MOSAIC Illumina next-generation sequencing platform used to analyse Pfdhfr , Pfdhps , PfK13 , Pfcrt and Pfmdr1 . Results In total, 1,731 samples were analysed. In the Pfdhfr gene, the triple mutant IRN I was detected at (> 90%) in all sites, and at Pfdhps , the single mutant 437G was recorded at > 90% in all sites. The novel emerging Pfdhps haplotype V A G K GS (which combines mutations 431 V , 437 G , 581 G and 613 S ) was detected at low prevalence in all sites, most commonly in Couffo (9%). The Pfmdr1 haplotypes NFD and N Y D (codon 86-184-1246) were widespread with NFD in the majority. The Pfcrt CV IET mutant haplotype was significantly more common in the south of Benin. Finally, no PfK13 WHO candidate or validated mutations were identified at any of the sites. Conclusion Our study captures the distribution of molecular markers of antimalarial drug resistance across Benin. The absence of PfK13 WHO candidate or validated mutations in any region is reassuring for the continuing use of ACTs, however the emergence of Pfdhps 431 V in the Pfdhps haplotype V A G K GS may present a challenge to the protective efficacy of SP-based chemoprevention in the future. Standardized maps of drug resistance in Benin provide support for sub-national tailoring of chemoprevention and treatment and a baseline for future surveillance.
Authors
- Ana Chopo-Pizarro (ORCID: https://orcid.org/0000-0002-4330-4085)
- Andria Mousa (ORCID: https://orcid.org/0000-0001-9406-7481)
- Augustin Kpemasse
- Corine Ngufor (ORCID: https://orcid.org/0000-0002-7755-9609)
- Azizath Moussiliou (ORCID: https://orcid.org/0000-0001-6736-9476)
- Khalid B. Beshir (ORCID: https://orcid.org/0000-0001-5108-8362)
- Cally Roper (ORCID: https://orcid.org/0000-0002-6545-309X)
- Michael Alifrangis (ORCID: https://orcid.org/0000-0002-3835-3333)
- Codjo Dandonougbo
- Colin Sutherland
- Louise Wellmann (ORCID: https://orcid.org/0009-0007-2836-5334)
- Helle Hansson
- Martin Akogbeto
- Rosario Martinez Vega
- R. Matthew Chico
- Cyriaque Affoukou
- Roland Gosling
Institutions
- University of Copenhagen (DK)
- Copenhagen University Hospital (DK)
- London School of Hygiene & Tropical Medicine (GB)
- Ministère de la Santé (TN)
- Ministère de la Santé (MA)
- Ministre de la Santé (BJ)
- Ministry of Health (RW)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-20
- DOI
- https://doi.org/10.21203/rs.3.rs-11594721/v1
- Primary Topic
- Malaria Research and Control
- Type
- preprint